Cellectar Biosciences (CLRB) Free Cash Flow (2010 - 2025)
Cellectar Biosciences (CLRB) posted Free Cash Flow of -$4.3 million for Q4 2025, down 1.61% sequentially from -$4.3 million in Q3 2025, and up 60.42% YoY from -$2.7 million in Q4 2024.
Cellectar Biosciences (CLRB) Free Cash Flow (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Free Cash Flow for 16 years, with the latest figure at -$4.3 million in Q4 2025.
- Quarterly Free Cash Flow rose 60.42% year-over-year to -$4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$23.1 million (up 51.52% YoY) and the FY2025 annual result came in at -$23.1 million, up 51.51% from the prior year.
- Free Cash Flow retreated to -$4.3 million in Q4 2025 per CLRB's latest filing, from -$4.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$4.3 million in Q3 2025 and troughed at -$14.2 million in Q2 2024.
- A 5-year average of -$7.6 million and a median of -$7.1 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Free Cash Flow sank 122.93% in 2021, then surged 63.88% in 2025.
- Over 5 years, Free Cash Flow stood at -$4.6 million in 2021, then tumbled by 62.25% to -$7.5 million in 2022, then plunged by 30.98% to -$9.9 million in 2023, then declined by 11.28% to -$11.0 million in 2024, then surged by 60.42% to -$4.3 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$4.3 million, -$4.3 million, and -$5.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.34 Mn |
| Dec 31, 2025 | -4.34 Mn |
| Sep 30, 2025 | -4.28 Mn |
| Sep 30, 2025 | -4.28 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Mar 31, 2025 | -9.38 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Dec 31, 2024 | -10.97 Mn |
| Sep 30, 2024 | -9.17 Mn |
| Sep 30, 2024 | -9.17 Mn |
| Jun 30, 2024 | -14.16 Mn |
| Jun 30, 2024 | -14.16 Mn |
| Mar 31, 2024 | -13.38 Mn |
| Mar 31, 2024 | -13.38 Mn |
| Dec 31, 2023 | -9.86 Mn |
| Dec 31, 2023 | -9.86 Mn |
| Sep 30, 2023 | -8.07 Mn |
| Sep 30, 2023 | -8.07 Mn |